A case of fugitive acromegaly, initially presented as invasive prolactinoma
- PMID: 20960094
- DOI: 10.1007/s12020-010-9341-5
A case of fugitive acromegaly, initially presented as invasive prolactinoma
Abstract
Fugitive acromegaly is most commonly caused by pituitary acidophil stem cell adenomas, and is characterized by a relatively short clinical history, a large and locally invasive tumor, and relatively low hormonal activity. Here, we report an unusual case of fugitive acromegaly that initially presented as invasive prolactinoma. A 48-year-old man with a huge pituitary mass extending to the suprasellar area was referred to our hospital in December 2007. He had undergone transsphenoidal surgery in November 1999 because of a large invasive prolactinoma. The tumor had grown progressively, despite therapy with dopamine agonists. Subtle features of acromegaly were noted and serum IGF-1 levels were high (733 ng/ml). An oral glucose tolerance test revealed that basal and nadir levels of growth hormone (GH) were 1.56 and 1 ng/ml, respectively. As a therapeutic trial, long-acting octreotide (20 mg IM, monthly) was added, and the tumor size markedly reduced within 6 months on magnetic resonance imaging examination. Immunohistochemical staining of the tumor tissue obtained at the surgery in 1999 showed positive staining for GH and prolactin (PRL). Double immunofluorescence staining showed a mixed positivity for GH and PRL in the majority of tumor cells; however, the two hormones colocalized in a minority of tumor cells, indicating that the tumor was composed of three different cell types (GH, PRL, and GH/PRL). The diagnosis of fugitive acromegaly was initially overlooked in this patient because of normal serum GH levels and a lack of acromegalic features, although histological evidence for GH production was present. IGF-1 determinations would be helpful for the diagnosis of fugitive acromegaly.
Similar articles
-
Acromegaly with normal basal growth hormone levels.Can J Neurol Sci. 1997 Aug;24(3):250-3. doi: 10.1017/s0317167100021892. Can J Neurol Sci. 1997. PMID: 9276113
-
Differences Between GH- and PRL-Cosecreting and GH-Secreting Pituitary Adenomas: a Series of 604 Cases.J Clin Endocrinol Metab. 2024 Nov 18;109(12):e2178-e2187. doi: 10.1210/clinem/dgae126. J Clin Endocrinol Metab. 2024. PMID: 38436926
-
Diagnosis, treatment, and outcome of pituitary tumors and other abnormal intrasellar masses. Retrospective analysis of 353 patients.Medicine (Baltimore). 1999 Jul;78(4):236-69. doi: 10.1097/00005792-199907000-00004. Medicine (Baltimore). 1999. PMID: 10424206
-
Acromegaly.Pituitary. 2006;9(4):297-303. doi: 10.1007/s11102-006-0409-4. Pituitary. 2006. PMID: 17077948 Review.
-
Pituitary surgery for the management of acromegaly.Horm Res. 2000;53 Suppl 3:71-5. doi: 10.1159/000023538. Horm Res. 2000. PMID: 10971109 Review.
Cited by
-
Clinical review: Pituitary carcinoma: difficult diagnosis and treatment.J Clin Endocrinol Metab. 2011 Dec;96(12):3649-60. doi: 10.1210/jc.2011-2031. Epub 2011 Sep 28. J Clin Endocrinol Metab. 2011. PMID: 21956419 Free PMC article. Review.
-
Primary hypothyroidism presenting as pseudoacromegaly.Pituitary. 2012 Dec;15 Suppl 1:S49-52. doi: 10.1007/s11102-011-0336-x. Pituitary. 2012. PMID: 21805092
-
A Brief Overview of Molecular Biology in Pituitary Adenomas with a Focus on Aggressive Lesions.Int J Mol Sci. 2025 Apr 15;26(8):3717. doi: 10.3390/ijms26083717. Int J Mol Sci. 2025. PMID: 40332351 Free PMC article. Review.
-
Overview of the 2017 WHO Classification of Pituitary Tumors.Endocr Pathol. 2017 Sep;28(3):228-243. doi: 10.1007/s12022-017-9498-z. Endocr Pathol. 2017. PMID: 28766057 Review.
-
Clinical Impact of the Current WHO Classification of Pituitary Adenomas.Endocr Pathol. 2016 Jun;27(2):104-14. doi: 10.1007/s12022-016-9418-7. Endocr Pathol. 2016. PMID: 26860936 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous